News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Hainan Honz Pharma's Main Product Faces Partial SFDA Ban



5/24/2011 12:58:26 PM

May 24, 2011 -- Hainan Honz Pharmaceutical announced its net income for the first half of 2011 will fall around 50%. The company has watched its stock price drop precipitously after its major product, Ruizhiqing, has been blamed for as many as seven deaths. Recently, the SFDA prohibited the use of the drug in children under 12. The drug is thought to cause liver damage and has been banned in many of the countries in which it was approved. More details....

Stock Symbol: (SHE: 300086)


Read at ChinaBio Today


comments powered by Disqus
SFDA
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES